智通财经APP讯,石四药集团(02005)公布,集团已取得中国国家药品监督管理局有关注射用左亚叶酸钙(25mg)的药品生产注册批件,属于化学药品第3类,视同通过一致性评价。左亚叶酸钙主要与5-氟尿嘧啶合用,用于治疗胃癌和结直肠癌。
智通财经APP讯,石四药集团(02005)公布,集团已取得中国国家药品监督管理局有关注射用左亚叶酸钙(25mg)的药品生产注册批件,属于化学药品第3类,视同通过一致性评价。左亚叶酸钙主要与5-氟尿嘧啶合用,用于治疗胃癌和结直肠癌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.